| FLKS - Flex Pharma Inc (Healthcare: Biotechnology) | Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-01-07) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| Flex Pharma Inc is a US-based biotechnology company which is engaged in the developing proprietary treatments for muscle cramps and spasms associated with severe neurological conditions and exercise-associated muscle cramps. The lead drug product candidate is FLX-787 which is a single molecule, chemically synthesized, TRP ion channel activator and HOTSHOT, which is developed to prevent and treat exercise-associated muscle cramps. The company operates through two segments - Consumer Operations and Drug Development. The Consumer Operations segment includes the development of HOTSHOT whereas the Drug Development segment includes the development of proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |